Vor Biopharma’s Leukemia Cell Exhibits Favorable Engraftment Five Months Post-Transplant
Vor Biopharma Inc (NASDAQ:VOR) presented clinical data from VBP101, its Phase 1/2a study of trem-cel (previously VOR33) in patients with acute…
First AML Patient Transplanted With Vor Bio’s Trem-Cel Demonstrated Durable Engraftment through Multiple Mylotarg Cycles At Initial Dose Level
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of Mylotarg
Mylotarg treatment enriched CD33-negative donor hematopoiesis
Second patient successfully received trem-cel
JMP Securities Maintains Market Outperform on Vor Biopharma, Lowers Price Target to $12
JMP Securities analyst Silvan Tuerkcan maintains Vor Biopharma (NASDAQ:VOR) with a Market Outperform and lowers the price target from $15 to $12.
Analyzing Vor Biopharma’s Short Interest
Vor Biopharma's (NASDAQ:VOR) short percent of float has fallen 58.58% since its last report. The company recently reported that it has 2.53 million shares sold short, which is 5.31% of all regular shares that are available for trading.
PureTech Health Plc Provides Update On Progress Made Across Its Wholly Owned Programs And Founded Entities In 2022
Rapid advancement of PureTech's Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral allopregnanolone).
Dow Edges Higher; Prometheus Biosciences Shares Jump
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 0.5% on Wednesday.
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC met the primary endpoint.
